Skip to main content
Clinical Trials/NCT05409391
NCT05409391
Completed
Not Applicable

Study to Assess the Efficacy and Safety of Insulin Titration System Based on Deep Learning on Glucose Control in Type 2 Diabetes Mellitus Patients

Shanghai Zhongshan Hospital1 site in 1 country16 target enrollmentJune 15, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus Type 2 - Insulin-Treated
Sponsor
Shanghai Zhongshan Hospital
Enrollment
16
Locations
1
Primary Endpoint
mean daily blood glucose concentration
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is an open-labeled, one-arm intervention trial to access the effect and safety of the Insulin Titration System Based on Deep Learning in patients with Type 2 Diabetes Mellitus.

Detailed Description

The study enrolls 13 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin. After screening for the inclusion and exclusion criteria, eligible patients will receive insulin dosage titration set by the Insulin Titration System Based on Deep Learning in the intervention trial. The goal of insulin therapy was to achieve preprandial capillary blood glucose between 5.6-7.8 mmol/L and postprandial capillary glucose less than 10.0mmol/L. All patients are studied for 5 consecutive days or untill hospital discharge. For each patient, capillary glucose concentration was measured at 7 time points of fasting, after breakfast, before and after lunch, before and after dinner, and before bedtime a day using Glucometer (Glupad, Sinomedisite, China). Capillary glucose measurements were performed by the nurse staff according to standard procedures with a point-of-care testing device, which is integrated into the HIS system. And continuous glucose monitoring (CGM) was performed using flash glucose monitoring (Abbott Freestyle Libre, USA) placed on the upper left arm. This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan University.

Registry
clinicaltrials.gov
Start Date
June 15, 2022
End Date
October 6, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Shanghai Zhongshan Hospital
Responsible Party
Principal Investigator
Principal Investigator

Xiaoying Li

Professor

Shanghai Zhongshan Hospital

Eligibility Criteria

Inclusion Criteria

  • type 2 diabetes
  • age of 18-75 years
  • HbA1c between 7.0% and 11.0%.

Exclusion Criteria

  • subjects with acute complications of diabetes, such as ketoacidosis or hyperglycemic hyperosmolar state;
  • BMI ≥ 45kg/m2;
  • women who are pregnant or breast-feeding;
  • subjects with severe cardiac, hepatic, renal diseases; subjects with any psychiatric or psychological diseases;
  • subjects with severe edema, infections or peripheral circulation disorders, receiving surgery during hospitalization;
  • subjects who could not comply with the protocol

Outcomes

Primary Outcomes

mean daily blood glucose concentration

Time Frame: 5 days

For each patient, capillary glucose concentration was measured at 7 time points of fasting, after breakfast, before and after lunch, before and after dinner, and before bedtime a day using Glucometer (Glupad, Sinomedisite, China). Capillary glucose measurements were performed by the nurse staff according to standard procedures with a point-of-care testing device, which is integrated into the HIS system. The primary outcome is the difference in glycemia control as measured by mean daily blood glucose concentration during the intervention period.

Secondary Outcomes

  • glucose concentration below range (3.0-3.8 mmol/L or <3.0 mmol/L)(5 days)
  • glycemic variability(5 days)
  • glucose concentration in target range (TIR) of 3.9-10.0 mmol/L(5 days)
  • glucose concentration above range (10.1-13.9 mmol/L or >13.9 mmol/L)(5 days)

Study Sites (1)

Loading locations...

Similar Trials